(s)-5-Pentenyl alanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (s)-5-Pentenyl alanine
• 英文别名: (2S)-2-[[(E)-pent-1-enyl]amino]propanoic acid
• 化学式: C₈H₁₅NO₂
• 分子量: 157.21
• InChiKey: RTIIDBURLHHYRK-XPPMVYLVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Modulation of hepatitis B virus replication
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US10684272B2

  公开（公告）日：2020-06-16

  Presently disclosed is a method of modulating Hepatitis B virus (HBV) replication, by contacting the cell with at least one agent that modulates at least one factor from a specified group consisting of SNAI2, SOX7 and other factors, the screening of said agent and use thereof in a medicament for treating HBV infection or disease or condition associated with a HBV infection in a subject. In one preferred embodiment, the agent is one peptide derived from SOX7 or SNAI2 or stapled peptides thereof. As a separate invention, a method of identifying at least one factor that modulates replication of a virus is also disclosed.

  目前公开的是一种调节乙型肝炎病毒（HBV）复制的方法，该方法通过使细胞与至少一种调节由SNAI2、SOX7和其他因子组成的指定组中至少一种因子的制剂接触，筛选所述制剂并将其用于治疗受试者HBV感染或与HBV感染相关的疾病或病症的药物中。在一个优选的实施方案中，所述制剂是一种源自 SOX7 或 SNAI2 的肽或其钉肽。作为一项单独的发明，还公开了一种鉴定至少一种调节病毒复制的因子的方法。
• Respiratory syncytial virus (RSV) replication inhibitors
  申请人：FONDATION THE ARK

  公开号：US10774114B2

  公开（公告）日：2020-09-15

  The invention provides polypeptides interacting with the binding of the RSV phosphoprotein P with the RSV nucleoprotein N and methods of using such polypeptides in the treatment and/or prevention of RSV infection.

  本发明提供了与 RSV 磷酸蛋白 P 与 RSV 核蛋白 N 结合相互作用的多肽，以及使用这种多肽治疗和/或预防 RSV 感染的方法。
• Peptides binding to Bfl-1
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US11078246B2

  公开（公告）日：2021-08-03

  This disclosure features stapled peptide inhibitors (e.g., cysteine-reactive stapled peptides) of the anti-apoptotic protein, BFL-1, and methods of using same in the treatment of BFL-1 expressing cancers.

  本公开的特点是抗凋亡蛋白BFL-1的钉状肽抑制剂（如半胱氨酸反应钉状肽），以及用其治疗表达BFL-1的癌症的方法。
• METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161A2

  公开（公告）日：2015-05-20
• DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161B1

  公开（公告）日：2020-12-16